U.S. stock futures slip lower; Cook’s firing increases Fed independence worries
Mark W. Sawicki, the Chief Scientific Officer of Cryoport, Inc. (NASDAQ:CYRX), recently sold 1,583 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The sale, which took place on March 10, 2025, was executed at an average price of $4.8791 per share, totaling approximately $7,723. The transaction comes as Cryoport’s stock shows significant volatility, with shares currently trading at $6.65, marking a notable 31% gain over the past week. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
This transaction follows a conversion of restricted stock rights to common stock, which occurred on March 9, 2025. Sawicki acquired 2,667 shares of common stock through this conversion, which did not involve any monetary exchange. The restricted stock rights, originally granted to vest in equal annual installments, converted to shares on a one-for-one basis. InvestingPro data shows the company maintains strong liquidity with a current ratio of 5.29, though analysts don’t expect profitability this year.
The sale of shares was required to cover taxes due upon the vesting of these restricted stock rights, as per Cryoport’s policies. Following these transactions, Sawicki holds 78,528 shares of Cryoport’s common stock. Get deeper insights into CYRX’s financial health and more exclusive tips with a InvestingPro subscription.
In other recent news, CryoPort Inc. reported its fourth-quarter 2024 financial results, revealing a mixed performance. The company posted a larger-than-expected loss per share of -0.42, missing the forecast of -0.29. However, CryoPort’s revenue exceeded expectations, reaching $59.53 million against the projected $58.64 million. Despite the earnings shortfall, the revenue beat has sparked interest among investors, with the company forecasting a revenue range of $240-$250 million for 2025. In the same period, Jefferies analyst Matthew Stanton adjusted the price target for CryoPort to $6.50 from $8.00, maintaining a Hold rating. Stanton noted that while the company’s fourth-quarter performance and 2025 revenue guidance are encouraging, investors may seek further clarity on growth strategies. CryoPort is targeting a return to positive adjusted EBITDA in 2025, driven by growth in life sciences services and new product launches. The company also highlighted the launch of new products and initial contracts for IntegraCell as part of its strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.